A novel diagnostic
giving transplant
patients new confidence.
We are advancing first-in-class, cell-based immune diagnostics—including Pleximmune™, the FDA-approved test that predicts transplant rejection. Our platform also detects viral infections and immune dysfunction, enabling more personalized and effective care for every patient.
OUR SCIENCE
Disrupting uncertainty in transplant and immune care
Plexision’s assays measure antigen-specific T-cell and B-cell activation using CD154 expression and flow cytometry, producing clear biomarkers such as the Index of Rejection and immune protection thresholds. Performed in our CLIA-certified lab with rapid turnaround, they guide confident, personalized transplant and immune care decisions while minimizing invasive procedures.
OUR PRODUCTS
Focused on addressing unmet needs in transplant and immune medicine.
Transplant Rejection
Pleximmune™, Pleximark™, PlexABMR™, PlexAPR™
Viral
Infections
PlexCMV™, PlexEBV™, PlexBKV™
Immune Deficiency & Immuno-Oncology
Antigen/Mitogen stimulation, Lymphocyte subsets, Drug selection support
Clinically meaningful outcomes
Earlier insight, fewer surprises:
ABMR and TCMR risk stratification improves prioritization of interventions that protect long‑term graft survival in kidney programs.
Smarter monitoring
CMV/EBV immunity results help determine when antiviral therapy can be safely de‑escalated or when intensified monitoring is warranted.
Pediatric advantage
FDA HDE authorization establishes a regulated pathway for personalized rejection risk prediction in children with liver and intestine transplants.
Truly novel.
Truly important.
We are on a mission to improve therapeutic outcomes for cancer patients with misetionamide, a tumor-cell selective agent with a truly novel mechanism of action.
Focused on what
matters most.
Our mission is to give clinicians and patients confidence in critical decisions. Every test is performed in our CLIA-certified Pittsburgh laboratory with rigorous quality controls and actionable reports.
From early rejection detection to antiviral immune readiness, Plexision diagnostics help personalize care when it matters most.
The Latest
PUBLICATION
Publication Summary – Misetionamide (GP-2250)
A summary of all publications with links to full document
POSTER
Publication Summary – Misetionamide (GP-2250)
Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors
PRESS RELEASE - 13 JUNE 2025
Publication Summary – Misetionamide (GP-2250)
A summary of all publications with links to full document
PRESS RELEASE - 14 NOVEMBER 2024
Publication Summary – Misetionamide (GP-2250)
Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors
+1.610.922.1910
Copyright © 2025 Panavance Therapeutics Inc.
Our Home
About
Resources
Participate